TITLE

Drug company experts advised staff to withhold data about SSRI use in children

AUTHOR(S)
Kondro, Wayne; Sibbald, Barbara
PUB. DATE
March 2004
SOURCE
CMAJ: Canadian Medical Association Journal;3/2/2004, Vol. 170 Issue 5, p783
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the internal document released by GlaxoSmithKline (GSK) that advised its staff to withhold clinical trial findings in 1998 that indicated the antidepressant paroxetine had no beneficial effect in treating adolescents. Reason for the decision of Great Britain and the U.S. to ban the pediatric use of paroxetine; Details included in the document; Comments from GSK spokeswoman Jill McKinlay-Morris on the document.
ACCESSION #
12304845

 

Related Articles

  • Manufacturing Consensus. Healy, David // Hastings Center Report;Jul/Aug2004, Vol. 34 Issue 4, p53 

    Focuses on the misuse of clinical trial data. Information on the GlaxoSmithKline clinical trial for the antidepressant drug paroxetine; Factor that led to the implementation of registry of all clinical trials; Way to maintain therapeutics as a science.

  • Out in the open.  // Nature Biotechnology;Feb2005, Vol. 23 Issue 2, p153 

    The article informs that until recently, biotech and pharmaceutical companies have had little reason to heed calls for greater transparency in the disclosure data from their clinical trials. That all changed last year when New York State attorney general Eliot Spitzer filed a high-profile...

  • Model-Based Approach and Signal Detection Theory to Evaluate the Performance of Recruitment Centers in Clinical Trials With Antidepressant Drugs. Merlo-Pich, E.; Gomeni, R. // Clinical Pharmacology & Therapeutics;Sep2008, Vol. 84 Issue 3, p378 

    The objective of this study was to characterize the performance of each recruitment center in multicenter clinical trials and to provide criteria to discriminate between informative and noninformative centers using the signal detection approach. Data were derived from the GlaxoSmithKline...

  • The Benefit of Transparent Trials. Krall, Ronald // Applied Clinical Trials;Oct2005, Vol. 14 Issue 10, p82 

    Advocates the full disclosure of clinical trial information. Transparency needed to ensure confidence in the reporting of industry-sponsored trials; Development of GSK Clinical Trial Register by GlaxoSmithKline PLC which provides information about all the sponsored trials of the company;...

  • How many good antidepressant medications have we missed? Blier, Pierre // Journal of Psychiatry & Neuroscience;Jul2004, Vol. 29 Issue 4, p248 

    This article focuses on antidepressant medications. Once antidepressant medications have been demonstrated to be safe for human use, they generally have to prove superior to placebo in at least 2 randomized, double-blind, placebo-controlled studies to be approved by regulatory agencies. It is...

  • Antidepressants and Violence: Problems at the Interface of Medicine and Law. Healy, David; Herxheimer, Andrew; Menkes, David B. // PLoS Medicine;Sep2006, Vol. 3 Issue 9, pe372 

  • Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data. Wernicke, Joachim; Pangallo, Beth; Fujun Wang; Murray, Isabelle; Henck, Judith W.; Knadler, Mary Pat; D'Souza, Deborah N.; Uetrecht, Jack P. // Current Drug Safety;May2008, Vol. 3 Issue 2, p132 

    Objective: Review nonclinical and clinical trial data for hepatic effects of duloxetine. Methods: Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Results: Nonclinical studies revealed no treatment-related transaminase elevations and no effects of duloxetine...

  • Translating comparative effectiveness of depression medications into practice by comparing the depression medication choice decision aid to usual care: study protocol for a randomized controlled trial. LeBlanc, Annie; Bodde, Amy E.; Branda, Megan E.; Yost, Kathleen J.; Herrin, Jeph; Williams, Mark D.; Shah, Nilay D.; Van Houten, Holly; Ruud, Kari L.; Pencille, Laurie J.; Montori, Victor M. // Trials;2013, Vol. 14 Issue 1, p1 

    Background: Comparative effectiveness research (CER) documents important differences in antidepressants in terms of efficacy, safety, cost, and burden to the patient. Decision aids can adapt this evidence to help patients participate in making informed choices. In turn, antidepressant therapy...

  • Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder--the EMC trial. Tadić, André; Gorbulev, Stanislav; Dahmen, Norbert; Hiemke, Christoph; Braus, Dieter F.; Röschke, Joachim; van Calker, Dietrich; Wachtlin, Daniel; Kronfeld, Kai; Gorbauch, Thorsten; Seibert-Grafe, Monika; Lieb, Klaus // Trials;2010, Vol. 11, p21 

    Background: In Major Depressive Disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics